{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-034843","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2023-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.135653+00:00","generated_at":"2026-06-17T22:00:21.673556+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVRx BeAT-HF trial: safety endpoint met, symptom improvement shown; primary endpoint not significant","bullets":["Safety: MANCE event-free rate of 97% (p<0.001).","Symptom improvement: 6-min walk +44m at 12mo, QoL +10 pts at 24mo (p<0.001).","Primary endpoint (CV death, LVAD, transplant, HF hospitalizations) not significant (RR 0.94, p=0.82).","All-cause mortality showed 34% relative reduction favoring BAT (HR 0.66, p=0.054).","CEO plans FDA submission in coming months for expanded labeling."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-034843","json":"https://secwatch.observer/filing/0001104659-23-034843.json","markdown":"https://secwatch.observer/filing/0001104659-23-034843.md","text":"https://secwatch.observer/filing/0001104659-23-034843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465923034843/0001104659-23-034843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465923034843/tm2310097d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T22:00:21.673556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}